Neoleukin Therapeutics Announces Oral Presentation at 64th American Society of Hematology (ASH) Annual Meeting
Neoleukin Therapeutics (NASDAQ:NLTX) announced an oral presentation at the American Society of Hematology (ASH) Annual Meeting scheduled for December 10-13, 2022, in New Orleans.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Neoleukin Therapeutics (NASDAQ:NLTX) announced an oral presentation at the American Society of Hematology (ASH) Annual Meeting scheduled for December 10-13, 2022, in New Orleans. The presentation titled NEO-TRA1 will focus on a CD25-targeted de novo non-Alpha Agonist of the IL-2 receptor, which selectively expands regulatory T cells. The session will take place on December 12, 2022, at 11:45 AM at the Ernest N. Morial Convention Center.
Neoleukin aims to innovate immunotherapies for cancer and autoimmune diseases through advanced protein design technology.
Positive
- Scheduled an oral presentation at the ASH Annual Meeting, indicating active engagement in the scientific community.
- Focus on innovative therapeutics, potentially enhancing investor confidence.
Negative
- None.
Details
News Market Reaction – NLTX
The recorded move for NLTX in the trading session of this news was -0.96%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SEATTLE, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced an oral presentation at the upcoming American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 10-13, 2022 in New Orleans, Louisiana.
Oral presentation details are as follows:
Title: NEO-TRA1: A CD25-Targeted De Novo non-Alpha Agonist of the IL-2 Receptor Selectively Expands Regulatory T Cells
Session Name: 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Delineating Immunity from Mice to Humans
Publication Number: 684
Session Date/Time: Monday, December 12, 2022, 11:45 AM
Location: Ernest N. Morial Convention Center, 278-282
About Neoleukin Therapeutics, Inc.
Neoleukin is a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity using de novo protein design technology. Neoleukin uses sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins. Neoleukin’s lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to improve tolerability and activity by eliminating the alpha receptor binding interface. For more information, please visit the Neoleukin website: www.neoleukin.com.
Contacts:
Media
Julie Rathbun
206-769-9219
jrathbun@neoleukin.com
Investors
Solebury Trout
Alexandra Roy
617-221-9197
aroy@soleburytrout.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.